MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.
City Of United Kingdom Jad Othman Molecular Minimal Residual Disease Following Induction Chemotherapy Patients With Npm1 Mutated Acute Myeloid Leukemia Allogeneic Transplant In First Remission
Source: onclive.com